Previous Close | 803,000.00 |
Open | 808,000.00 |
Bid | 802,000.00 x 0 |
Ask | 803,000.00 x 0 |
Day's Range | 798,000.00 - 808,000.00 |
52 Week Range | 668,000.00 - 880,000.00 |
Volume | |
Avg. Volume | 63,165 |
Market Cap | 57.153T |
Beta (5Y Monthly) | 0.45 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | Jul 24, 2024 - Jul 29, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1,030,380.00 |
Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2024.
Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), and managed by Samsung Ventures, and BrickBio, Inc. announced Samsung's investment in BrickBio, a preclinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code.
Q4 2023 Rapid Micro Biosystems Inc Earnings Call